Publications by authors named "Kristian Bolanos"
Article Synopsis
- Progress in treating solid tumors has been limited by the absence of unique targets; however, a new T cell therapy called Tmod™ addresses this challenge by utilizing a dual-receptor system.
- The Tmod system leverages a genetic difference known as loss of heterozygosity (LOH) to distinguish between tumor and normal cells, using both a chimeric antigen receptor (CAR) or T cell receptor (TCR) for activation and a modified inhibitory receptor to enhance selectivity.
- This study investigates a blocker targeting the HLA-A*02 antigen alongside two different T-mod constructs and reveals that Tmod functions through mechanisms that reduce receptor sensitivity and activation strength, making it more robust to changes in antigen expression on target cells.
Background: Mesothelin (MSLN) is a classic tumor-associated antigen that is expressed in lung cancer and many other solid tumors. However, MSLN is also expressed in normal mesothelium which creates a significant risk of serious inflammation for MSLN-directed therapeutics. We have developed a dual-receptor (Tmod™) system that exploits the difference between tumor and normal tissue in a subset of patients with defined heterozygous gene loss (LOH) in their tumors.
View Article and Find Full Text PDF